Producing better antiviral peptide vaccines

Natural viral proteins cannot constantly be used as optimal vaccines because they do not always stimulate efficiently the immune system. In December 1 Journal of Clinical Investigation, Jeffrey Ahlers and colleagues from National Institutes of Health, Bethesda, USA, show that sequence modification of natural viral proteins to increase epitope affinity for class II MHC molecules (epitope enhancement) can improve immunogenicity.Ahlers et al. found that modification of a Th cell epitope to increase

Tudor Toma(t.toma@ic.ac.uk)
Dec 18, 2001

Natural viral proteins cannot constantly be used as optimal vaccines because they do not always stimulate efficiently the immune system. In December 1 Journal of Clinical Investigation, Jeffrey Ahlers and colleagues from National Institutes of Health, Bethesda, USA, show that sequence modification of natural viral proteins to increase epitope affinity for class II MHC molecules (epitope enhancement) can improve immunogenicity.

Ahlers et al. found that modification of a Th cell epitope to increase binding to MHC causes quantitatively more T cells to undergo upregulation of CD40 ligant. This induced more polarizing antigen presenting cells that act back on the T helper cell to produce a Th1-polarized response, as well as higher levels of cytotoxic T lymphocytes and protection against viral infection (J Clin Invest 2001, 108:1677-1685).

"If such enhanced epitopes can be shown to activate costimulatory pathways and to increase Th1 polarization in other settings,...

Interested in reading more?

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?